Literature DB >> 9746335

Metabolic control analysis and mitochondrial pathologies.

T Letellier1, M Malgat, R Rossignol, J P Mazat.   

Abstract

One of the main salient features recognized in mitochondrial diseases is the existence of a threshold in the degree of a mitochondrial deficit for the expression of the disease. When expressed as a function of the degree of heteroplasmy, the value of the threshold can be very high, around 90% (mutated DNA/total DNA). This means that 10% of normal DNA is enough to sustain a quasi normal mitochondrial oxidative phosphorylating flux. We have shown that most of the compensation is done at the metabolic level: for instance a 70% deficit of cytochrome oxidase decreases the oxidative flux by just 10%. Similar patterns are observed for the other complexes. Using Metabolic Control Analysis (MCA), we have shown that this kind of result is inescapable: the threshold value can be correlated to the control coefficient of the deficient step. The value of the threshold is reinforced by slight increases at the transcriptional and translational level as we show in a simple mathematical model. Finally we associate the threshold in the expression of a deficit, to the threshold in the energy demand of different tissues, in order to describe various patterns of onset of mitochondrial diseases (double threshold hypothesis).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746335

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

Review 1.  Diseases of the mitochondrial DNA.

Authors:  D C Wallace
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

2.  Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction.

Authors:  J Hayashi; S Ohta; A Kikuchi; M Takemitsu; Y Goto; I Nonaka
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Why are most flux control coefficients so small?

Authors:  J P Mazat; C Reder; T Letellier
Journal:  J Theor Biol       Date:  1996-10-07       Impact factor: 2.691

4.  A linear steady-state treatment of enzymatic chains. General properties, control and effector strength.

Authors:  R Heinrich; T A Rapoport
Journal:  Eur J Biochem       Date:  1974-02-15

5.  Mitochondrial genome expression in a mutant strain of D. subobscura, an animal model for large scale mtDNA deletion.

Authors:  F Beziat; F Morel; A Volz-Lingenhol; N Saint Paul; S Alziari
Journal:  Nucleic Acids Res       Date:  1993-02-11       Impact factor: 16.971

6.  The relationship between mitochondrial genotype and mitochondrial phenotype in lymphoblasts with a heteroplasmic mtDNA deletion.

Authors:  J N Spelbrink; B A Van Oost; C Van den Bogert
Journal:  Hum Mol Genet       Date:  1994-11       Impact factor: 6.150

7.  The molecular basis of dominance.

Authors:  H Kacser; J A Burns
Journal:  Genetics       Date:  1981 Mar-Apr       Impact factor: 4.562

8.  Mitochondrial genetics: a paradigm for aging and degenerative diseases?

Authors:  D C Wallace
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

Review 9.  Mitochondrial DNA variation in human populations and implications for detection of mitochondrial DNA mutations of pathological significance.

Authors:  A Torroni; D C Wallace
Journal:  J Bioenerg Biomembr       Date:  1994-06       Impact factor: 2.945

10.  Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy.

Authors:  M Sciacco; E Bonilla; E A Schon; S DiMauro; C T Moraes
Journal:  Hum Mol Genet       Date:  1994-01       Impact factor: 6.150

View more
  7 in total

1.  Tissue variation in the control of oxidative phosphorylation: implication for mitochondrial diseases.

Authors:  R Rossignol; T Letellier; M Malgat; C Rocher; J P Mazat
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

2.  Effect of 'binary mitochondrial heteroplasmy' on respiration and ATP synthesis: implications for mitochondrial diseases.

Authors:  B Korzeniewski; M Malgat; T Letellier; J P Mazat
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

3.  Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.

Authors:  Catherine H Le; Lindsay G Benage; Kalyn S Specht; Lance C Li Puma; Christopher M Mulligan; Adam L Heuberger; Jessica E Prenni; Steven M Claypool; Kathryn C Chatfield; Genevieve C Sparagna; Adam J Chicco
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

4.  Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain.

Authors:  H Sanchez; J Zoll; X Bigard; V Veksler; B Mettauer; E Lampert; J Lonsdorfer; R Ventura-Clapier
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 5.  Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity.

Authors:  V Calabrese; G Scapagnini; A M Giuffrida Stella; T E Bates; J B Clark
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

6.  Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes.

Authors:  Vittorio Calabrese; Carolin Cornelius; Anna Maria Giuffrida Stella; Edward J Calabrese
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

7.  Modeling of mitochondria bioenergetics using a composable chemiosmotic energy transduction rate law: theory and experimental validation.

Authors:  Ivan Chang; Margit Heiske; Thierry Letellier; Douglas Wallace; Pierre Baldi
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.